Bioniche Life Sciences has released data showing that repeated intraperitoneal administration of Urocidin is well-tolerated and results in significant anticancer activity against peritoneal colon carcinomatosis in rats.
A preclinical evaluation study investigated the tolerability and anticancer activity of the mycobacterial cell wall-DNA complex (MCC) suspension, trademarked Urocidin, after intraperitoneal administration using a rat peritoneal DHD/K12/PROb colon carcinomatosis model.
Preliminary data from this study, suggesting a possible anticancer activity of MCC suspension against peritoneal colon cancer, was previously reported last year. New and updated data evaluating the survival efficacy of MCC suspension for a period of 12 months in animals with peritoneal colon cancer confirm and demonstrate a marked anticancer activity of MCC suspension in this model.